Archana Asundi1, Alina Beliavsky2, Xing Jian Liu2, Arash Akaberi3, Guido Schwarzer4, Zeno Bisoffi5, Ana Requena-Méndez6, Ian Shrier3, Christina Greenaway7. 1. Division of Infectious Diseases, Boston Medical Center, Boston, USA. 2. Department of Internal Medicine, McGill University, Montreal, QC, Canada. 3. Centre for Clinical Epidemiology of the Lady Davis Institute for Medical Research, McGill University, Montreal, QC, Canada. 4. Institute of Medical Biometry and Statistics, Faculty of Medicine and Medical Center, University of Freiburg, Freiburg, Germany. 5. Centre for Tropical Diseases, IRCCS Sacro Cuore Don Calabria Hospital, Negrar, Verona, Italy; Department of Diagnostics and Public Health, University of Verona, Verona, Italy. 6. Barcelona Institute for Global Health, Universitat de Barcelona-Hospital Clinic, Barcelona, Spain. 7. Centre for Clinical Epidemiology of the Lady Davis Institute for Medical Research, McGill University, Montreal, QC, Canada; Division of Infectious Diseases and Clinical Epidemiology, SMBD Jewish General Hospital, McGill University, Montreal, QC, Canada. Electronic address: ca.greenaway@mcgill.ca.
Abstract
BACKGROUND: Global migration from regions where strongyloidiasis and schistosomiasis are endemic to non-endemic countries has increased the potential individual and public health effect of these parasitic diseases. We aimed to estimate the prevalence of these infections among migrants to establish which groups are at highest risk and who could benefit from screening. METHODS: We did a systematic review and meta-analysis of strongyloidiasis and schistosomiasis prevalence among migrants born in endemic countries. Original studies that included data for the prevalence of Strongyloides or Schistosoma antibodies in serum or the prevalence of larvae or eggs in stool or urine samples among migrants originating from countries endemic for these parasites and arriving or living in host countries with low endemicity-specifically the USA, Canada, Australia, New Zealand, Israel, and 23 western European countries-were eligible for inclusion. Pooled estimates of the prevalence of strongyloidiasis and schistosomiasis by stool or urine microscopy for larvae or eggs or serum antibodies were calculated with a random-effects model. Heterogeneity was explored by stratification by age, region of origin, migrant class, period of study, and type of serological antigen used. FINDINGS: 88 studies were included. Pooled strongyloidiasis seroprevalence was 12·2% (95% CI 9·0-15·9%; I2 96%) and stool-based prevalence was 1·8% (1·2-2·6%; 98%). Migrants from east Asia and the Pacific (17·3% [95% CI 4·1-37·0]), sub-Saharan Africa (14·6% [7·1-24·2]), and Latin America and the Caribbean (11·4% [7·8-15·7]) had the highest seroprevalence. Pooled schistosomiasis seroprevalence was 18·4% (95% CI 13·1-24·5; I2 97%) and stool-based prevalence was 0·9% (0·2-1·9; 99%). Sub-Saharan African migrants had the highest seroprevalence (24·1·% [95% CI 16·4-32·7]). INTERPRETATION: Strongyloidiasis affects migrants from all global regions, whereas schistosomiasis is focused in specific regions and most common among sub-Saharan African migrants. Serological prevalence estimates were several times higher than stool estimates for both parasites. These data can be used to inform screening decisions for migrants and support the use of serological screening, which is more sensitive and easier than stool testing. FUNDING: None.
BACKGROUND: Global migration from regions where strongyloidiasis and schistosomiasis are endemic to non-endemic countries has increased the potential individual and public health effect of these parasitic diseases. We aimed to estimate the prevalence of these infections among migrants to establish which groups are at highest risk and who could benefit from screening. METHODS: We did a systematic review and meta-analysis of strongyloidiasis and schistosomiasis prevalence among migrants born in endemic countries. Original studies that included data for the prevalence of Strongyloides or Schistosoma antibodies in serum or the prevalence of larvae or eggs in stool or urine samples among migrants originating from countries endemic for these parasites and arriving or living in host countries with low endemicity-specifically the USA, Canada, Australia, New Zealand, Israel, and 23 western European countries-were eligible for inclusion. Pooled estimates of the prevalence of strongyloidiasis and schistosomiasis by stool or urine microscopy for larvae or eggs or serum antibodies were calculated with a random-effects model. Heterogeneity was explored by stratification by age, region of origin, migrant class, period of study, and type of serological antigen used. FINDINGS: 88 studies were included. Pooled strongyloidiasis seroprevalence was 12·2% (95% CI 9·0-15·9%; I2 96%) and stool-based prevalence was 1·8% (1·2-2·6%; 98%). Migrants from east Asia and the Pacific (17·3% [95% CI 4·1-37·0]), sub-Saharan Africa (14·6% [7·1-24·2]), and Latin America and the Caribbean (11·4% [7·8-15·7]) had the highest seroprevalence. Pooled schistosomiasis seroprevalence was 18·4% (95% CI 13·1-24·5; I2 97%) and stool-based prevalence was 0·9% (0·2-1·9; 99%). Sub-Saharan African migrants had the highest seroprevalence (24·1·% [95% CI 16·4-32·7]). INTERPRETATION:Strongyloidiasis affects migrants from all global regions, whereas schistosomiasis is focused in specific regions and most common among sub-Saharan African migrants. Serological prevalence estimates were several times higher than stool estimates for both parasites. These data can be used to inform screening decisions for migrants and support the use of serological screening, which is more sensitive and easier than stool testing. FUNDING: None.
Authors: Nerea Castillo-Fernández; Manuel J Soriano-Pérez; Ana B Lozano-Serrano; José C Sánchez-Sánchez; Antonio Villarejo-Ordóñez; José A Cuenca-Gómez; José Vázquez-Villegas; María I Cabeza-Barrera; Joaquín Salas-Coronas Journal: Infection Date: 2021-05-04 Impact factor: 3.553
Authors: Samuel De l'Étoile-Morel; Faheel Naeem; Mohammad Alghounaim; Makeda Semret; Cedric P Yansouni; Michael D Libman; Sapha Barkati Journal: Am J Trop Med Hyg Date: 2022-07-05 Impact factor: 3.707
Authors: Francesca Tamarozzi; Veronica A Fittipaldo; Hans Martin Orth; Joachim Richter; Dora Buonfrate; Niccolò Riccardi; Federico G Gobbi Journal: PLoS Negl Trop Dis Date: 2021-03-25
Authors: Philip Erick Wikman-Jorgensen; Jara Llenas-Garcia; Jad Shedrawy; Joaquim Gascon; Jose Muñoz; Zeno Bisoffi; Ana Requena-Mendez Journal: BMJ Glob Health Date: 2020-05
Authors: Dora Buonfrate; Donal Bisanzio; Giovanni Giorli; Peter Odermatt; Thomas Fürst; Christina Greenaway; Michael French; Richard Reithinger; Federico Gobbi; Antonio Montresor; Zeno Bisoffi Journal: Pathogens Date: 2020-06-13
Authors: Piet Cools; Lisette van Lieshout; Rob Koelewijn; David Addiss; Sitara S R Ajjampur; Mio Ayana; Richard S Bradbury; Jason L Cantera; Daniel Dana; Kerstin Fischer; Rubina Imtiaz; Joyce Kabagenyi; James Lok; James McCarthy; Rojelio Mejia; Zeleke Mekonnen; Sammy M Njenga; Nurulhasanah Othman; Hongguang Shao; Rebecca Traub; Marjan Van Esbroeck; Jozef Vercruysse; Johnny Vlaminck; Steven A Williams; Jaco J Verweij; Jaap J van Hellemond; Bruno Levecke Journal: PLoS Negl Trop Dis Date: 2020-06-16